LINCOLN vs ORTINGLOBE: Stock Comparison
LINCOLN PHARMA is the larger company by market capitalisation. LINCOLN PHARMA shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
LINCOLN leads 11; ORTINGLOBE leads 0 of 11
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | LINCOLN | ORTINGLOBE |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | LINCOLN | ORTINGLOBE |
|---|---|---|
| Live Price | ₹620.8 | ₹15.67 |
| Day Change | -0.3% | 4.33% |
| Volume | 29,091 | 9,743 |
| 52-Week High | ₹770 | ₹21.3 |
| 52-Week Low | ₹440 | ₹11 |
| Distance from 52W High | -19.38% | -26.43% |
Valuation
| Metric | LINCOLN | ORTINGLOBE |
|---|---|---|
| Market Cap | ₹1,240 Cr | ₹12 Cr |
| P/E Ratio | 12.83x | — |
| P/B Ratio | 1.63x | — |
| EPS | ₹18.09 | ₹-0.42 |
| Book Value | ₹378.25 | ₹1.52 |
| Dividend Yield | 0.3% | 0% |
Growth
| Metric | LINCOLN | ORTINGLOBE |
|---|---|---|
| Revenue Growth (TTM YoY) | 11.4% | -76.86% |
| EPS Growth (TTM YoY) | 0.6% | 0% |
| Qtr Sales Growth | 0% | -66.28% |
| Qtr Profit Growth | 0% | -3,533.33% |
Profitability & Leverage
| Metric | LINCOLN | ORTINGLOBE |
|---|---|---|
| ROE | 11.6% | -59.85% |
| ROCE | 11.97% | -44.08% |
| Net Margin | 13.1% | -529.87% |
| Operating Margin | 17.38% | -717.61% |
| Debt to Equity | 0.01x | 0.81x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | LINCOLN | ORTINGLOBE |
|---|---|---|
| Promoter Holding | 49.78% | 1.23% |
| FII Holding | 4.6%▼ 0.59 pp | 1.8%▲ 0.12 pp |
| DII Holding | 0.27%▼ 0.82 pp | 0% |
| Public Holding | 45.36%▲ 1.42 pp | 96.96%▼ 0.13 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: LINCOLN PHARMA and ORTIN GLOBAL.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.